Results 1 to 10 of about 16,074 (191)

SF3B1 Association with Chromatin Determines Splicing Outcomes [PDF]

Cell Reports, 2015
Much remains unknown concerning the mechanism by which the splicing machinery pinpoints short exons within intronic sequences and how splicing factors are directed to their pre-mRNA targets.
Nir Kfir, Galit Lev-Maor, Ohad Glaich, Adi Alajem, Arnab Datta, Siu K. Sze, Eran Meshorer, Gil Ast   +7 more
doaj   +2 more sources

Splicing Factor 3B Subunit 1 Interacts with HIV Tat and Plays a Role in Viral Transcription and Reactivation from Latency [PDF]

mBio, 2018
The main obstacle to an HIV cure is the transcriptionally inert proviruses that persist in resting CD4 T cells and other reservoirs. None of the current approaches has significantly reduced the size of the viral reservoir.
George B. Kyei, Shanshan Meng, Rashmi Ramani, Austin Niu, Chandraiah Lagisetti, Thomas R. Webb, Lee Ratner   +6 more
doaj   +3 more sources

U2AF65-Dependent SF3B1 Function in SMN Alternative Splicing [PDF]

Cells, 2020
Splicing factor 3b subunit 1 (SF3B1) is an essential protein in spliceosomes and mutated frequently in many cancers. While roles of SF3B1 in single intron splicing and roles of its cancer-linked mutant in aberrant splicing have been identified to some ...
Namjeong Choi, Yongchao Liu, Jagyeong Oh, Jiyeon Ha, Xuexiu Zheng, Haihong Shen   +5 more
doaj   +2 more sources

Advancing the therapeutic effectiveness of paclitaxel in chronic lymphocytic leukemia through the simultaneous inhibition of NOTCH1 and SF3B1 [PDF]

Cancer Cell International
Background Chemoresistance is still a significant obstacle to cancer therapy. Overexpression of the splicing factor 3b subunit 1 (SF3B1) and neurogenic locus notch homolog protein 1 (NOTCH1) factors is typically found in chronic lymphocytic leukemia (CLL)
Shiva Abolhasani, Armin Mahmoud salehi Khesht, Atefeh Khodakarami, Ali Masjedi, Bentolhoda Rashidi, Sepideh Izadi, Fatemeh Karimian Noukabadi, Vahid Karpisheh, Khatereh Torabi Poudeh, Pooya Jalali, Zahra Salehi, Rafieh Bagherifar, Seyyed Sina Hejazian, AliAkbar Movassaghpour, Abbas Ali Hosseinpour Feizi, Farhad Jadidi   +15 more
doaj   +2 more sources

Identification of UBA7 expression downregulation in myelodysplastic neoplasm with SF3B1 mutations [PDF]

Scientific Reports
SF3B1 gene mutations are prevalent in myelodysplastic syndrome (MDS) and define a distinct disease subtype. These mutations are associated with dysregulated genes and pathways, offering potential for novel therapeutic approaches.
Sael Alatawi, Othman R. Alzahrani, Fuad A. Alatawi, Ibrahim A. Almazni, Alhomidi Almotiri, Fahad M. Almsned   +5 more
doaj   +2 more sources

Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1

Haematologica, 2013
Somatic mutations of the RNA splicing machinery have been recently identified in myelodysplastic syndromes. In particular, a strong association has been found between SF3B1 mutation and refractory anemia with ring sider-oblasts, a condition characterized
Ilaria Ambaglio, Luca Malcovati, Elli Papaemmanuil, Coby M. Laarakkers, Matteo G. Della Porta, Anna Gallì, Matteo C. Da Vià, Elisa Bono, Marta Ubezio, Erica Travaglino, Riccardo Albertini, Peter J. Campbell, Dorine W. Swinkels, Mario Cazzola   +13 more
doaj   +3 more sources

Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3′ Splice Site Selection through Use of a Different Branch Point

Cell Reports, 2015
Recurrent mutations in the spliceosome are observed in several human cancers, but their functional and therapeutic significance remains elusive. SF3B1, the most frequently mutated component of the spliceosome in cancer, is involved in the recognition of ...
Rachel B. Darman, Michael Seiler, Anant A. Agrawal, Kian H. Lim, Shouyong Peng, Daniel Aird, Suzanna L. Bailey, Erica B. Bhavsar, Betty Chan, Simona Colla, Laura Corson, Jacob Feala, Peter Fekkes, Kana Ichikawa, Gregg F. Keaney, Linda Lee, Pavan Kumar, Kaiko Kunii, Crystal MacKenzie, Mark Matijevic, Yoshiharu Mizui, Khin Myint, Eun Sun Park, Xiaoling Puyang, Anand Selvaraj, Michael P. Thomas, Jennifer Tsai, John Y. Wang, Markus Warmuth, Hui Yang, Ping Zhu, Guillermo Garcia-Manero, Richard R. Furman, Lihua Yu, Peter G. Smith, Silvia Buonamici   +35 more
doaj   +2 more sources

Distinct routes of clonal progression in SF3B1-mutant myelodysplastic syndromes [PDF]

Blood Advances
: Myelodysplastic syndromes (MDS) are clonal stem cell disorders driven by heterogeneous genetic alterations leading to variable clinical course. MDS with splicing factor SF3B1 mutations is a distinct subtype with a favorable outcome.
Martina Sarchi, Courtnee A. Clough, Anna Gallì, Cristina Picone, Beatrice Ferrari, Edie I. Crosse, Laura D. Baquero Galvis, Claudia Fiducioso, Nelli Aydinyan, J. Philip Creamer, Sara Pozzi, Elisabetta Molteni, Chiara Elena, Robert K. Bradley, Luca Malcovati, Sergei Doulatov   +15 more
doaj   +2 more sources

CHIC: A machine learning framework for inferring the presence of high‐risk clonal hematopoiesis using complete blood count data from 431,531 UK Biobank participants [PDF]

Hemasphere
HemaSphere, Volume 9, Issue 7, July 2025.
Dunn W, Withnell I, Gu M, Quiros P, Cheloor Kovilakam S, Marando L, Wen S, Fabre M, Mohorianu I, Vuckovic D, Vassiliou G.   +10 more
europepmc   +2 more sources

Real-life experience of luspatercept in transfusion-dependent lower risk myelodysplastic syndrome patients. [PDF]

Br J Haematol
This retrospective multicentre study included 98 TD LR‐MDS patients who had failed prior erythropoietin treatment and were subsequently treated with luspatercept. Red blood cell (RBC) transfusion requirements were recorded in the last 16 weeks before luspatercept initiation and response rates consecutively declined in patient groups receiving 1–2 ...
Bouchla A, Papageorgiou SG, Kotsianidis I, Diamantopoulos P, Gavriilaki E, Bouronikou E, Symeonidis A, Zikos P, Cetiner M, Vlachaki E, Kostourou A, Galanopoulos A, Hatzimichael E, Vervesou EC, Bozdağ SC, Viniou NA, Christoulas D, Dellatola M, Papaioannou M, Papoutselis M, Vlachopoulou D, Syrigou A, Mainou M, Chatzileontiadou S, Pappa V.   +24 more
europepmc   +2 more sources